Free Trial

Galmed Pharmaceuticals (GLMD) Competitors

Galmed Pharmaceuticals logo
$1.47 +0.01 (+0.68%)
Closing price 03:59 PM Eastern
Extended Trading
$1.50 +0.03 (+2.04%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GLMD vs. ERNA, GNPX, EPIX, PCSA, INAB, DWTX, AEON, KPRX, CELZ, and APRE

Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Ernexa Therapeutics (ERNA), Genprex (GNPX), ESSA Pharma (EPIX), Heatwurx (PCSA), IN8bio (INAB), Dogwood Therapeutics (DWTX), AEON Biopharma (AEON), Kiora Pharmaceuticals (KPRX), Creative Medical Technology (CELZ), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry.

Galmed Pharmaceuticals vs. Its Competitors

Ernexa Therapeutics (NASDAQ:ERNA) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Galmed Pharmaceuticals has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Ernexa Therapeutics' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ernexa Therapeutics-7,652.75% N/A -682.08%
Galmed Pharmaceuticals N/A -20.69%-18.41%

Galmed Pharmaceuticals has lower revenue, but higher earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ernexa Therapeutics$580K16.00-$44.54M-$8.31-0.15
Galmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.09

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 4.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ernexa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Galmed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Ernexa Therapeutics has a beta of 5.66, suggesting that its stock price is 466% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

In the previous week, Ernexa Therapeutics had 2 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 2 mentions for Ernexa Therapeutics and 0 mentions for Galmed Pharmaceuticals. Ernexa Therapeutics' average media sentiment score of 0.00 equaled Galmed Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ernexa Therapeutics Neutral
Galmed Pharmaceuticals Neutral

Summary

Galmed Pharmaceuticals beats Ernexa Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLMD vs. The Competition

MetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.42M$2.57B$5.80B$10.46B
Dividend YieldN/A55.05%5.61%4.57%
P/E Ratio-0.095.29267.4622.91
Price / SalesN/A712.83549.90125.65
Price / CashN/A27.8326.0131.15
Price / Book0.155.3615.536.50
Net Income-$7.52M$32.95M$3.29B$271.25M
7 Day Performance0.68%3.96%200.87%3.69%
1 Month Performance-1.34%5.27%184.38%8.07%
1 Year Performance-84.28%-0.72%325.51%29.65%

Galmed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLMD
Galmed Pharmaceuticals
0.6274 of 5 stars
$1.47
+0.7%
N/A-84.4%$2.42MN/A-0.0920Gap Up
ERNA
Ernexa Therapeutics
0.4759 of 5 stars
$1.18
-8.5%
N/A-93.1%$9.90M$580K-0.1410Gap Down
High Trading Volume
GNPX
Genprex
0.7439 of 5 stars
$0.28
-5.7%
N/A-39.1%$9.76MN/A0.0020
EPIX
ESSA Pharma
2.6906 of 5 stars
$0.19
-5.2%
$2.00
+940.0%
-96.7%$9.60MN/A-0.3450Dividend Announcement
Gap Up
PCSA
Heatwurx
2.9791 of 5 stars
$0.20
+5.7%
$1.00
+399.0%
-85.8%$9.55MN/A-0.0920Positive News
INAB
IN8bio
2.7131 of 5 stars
$2.00
-4.8%
$180.00
+8,900.0%
-78.8%$9.53MN/A-0.2220Gap Up
DWTX
Dogwood Therapeutics
1.3832 of 5 stars
$4.93
+0.8%
$10.00
+102.8%
N/A$9.35MN/A-0.265Positive News
AEON
AEON Biopharma
3.3299 of 5 stars
$0.79
+1.3%
$360.00
+45,446.6%
-98.5%$9.20MN/A4.395Gap Down
KPRX
Kiora Pharmaceuticals
2.6415 of 5 stars
$2.61
-1.1%
$10.00
+283.1%
-30.9%$9.06M$16.02M-0.9010Gap Up
CELZ
Creative Medical Technology
0.783 of 5 stars
$3.48
-0.6%
N/A+12.5%$9.03M$10K-1.095Positive News
APRE
Aprea Therapeutics
2.667 of 5 stars
$1.51
-2.2%
$15.50
+926.5%
-54.0%$8.99M$1.50M-0.657

Related Companies and Tools


This page (NASDAQ:GLMD) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners